Shibata Shigeru, Akasaka Harue, Wakiya Taiichi, Yamanaka Yuji, Narita Junichi, Sutou Takemichi, Iino Chikara
Dept. of Surgery, Hirosaki Municipal Hospital.
Gan To Kagaku Ryoho. 2014 Nov;41(12):2396-8.
A man in his seventies presented with a stomach abnormality that was revealed upon physical examination.Following workup, he was diagnosed with gastric diffuse large B-cell lymphoma (DLBCL)StageII1 (Lugano staging system for gastrointestinal lymphoma) with low risk as defined by the International Prognostic Index criteria.The entire stomach showed an intense, abnormal FDG uptake by FDG-PET evaluation.He was treated with rituximab plus CHOP (R-CHOP).The patient's body weight decreased by 12 kg during the treatment period.Post -treatment evaluation by gastroscopy and FDG-PET following 5 courses of R-CHOP therapy revealed a residual lesion in the stomach.Total gastrectomy was performed for R-CHOP refractory gastric DLBCL.The pathological diagnosis was DLBCL, and the pathological therapeutic effect was Grade 1a.Lymphoma cells were detected at the duodenal margin of the resected specimen, and an FDG-PET scan showed abnormal FDG uptake in the duodenal stump necessitating salvage chemotherapy (DeVIC therapy)and radiotherapy.The patient's body weight increased by 5 kg after gastrectomy and there were no signs of relapse for 14 months after the operation.Salvage therapy including gastrectomy may be effective for chemotherapy-resistant gastric DLBCL.
一名七十多岁的男性在体格检查时发现胃部异常。经过检查,他被诊断为胃弥漫性大B细胞淋巴瘤(DLBCL),根据国际预后指数标准,为Ⅲ期(胃肠道淋巴瘤的卢加诺分期系统)低风险。FDG-PET评估显示整个胃部有强烈的异常FDG摄取。他接受了利妥昔单抗联合CHOP(R-CHOP)治疗。治疗期间患者体重下降了12公斤。在接受5个疗程的R-CHOP治疗后,通过胃镜和FDG-PET进行的治疗后评估显示胃部有残留病变。对R-CHOP难治性胃DLBCL进行了全胃切除术。病理诊断为DLBCL,病理治疗效果为1a级。在切除标本的十二指肠边缘检测到淋巴瘤细胞,FDG-PET扫描显示十二指肠残端有异常的FDG摄取,因此需要进行挽救性化疗(DeVIC疗法)和放疗。胃切除术后患者体重增加了5公斤,术后14个月没有复发迹象。包括胃切除术在内的挽救性治疗可能对化疗耐药的胃DLBCL有效。